Last Price
40.19
Today's Change
-0.065 (0.16%)
Day's Change
39.79 - 41.14
Trading Volume
37,020
Market Cap
2 Billion
Shares Outstanding
68 Million
Avg Volume
618,253
Avg Price (50 Days)
42.09
Avg Price (200 Days)
49.03
PE Ratio
-9.90
EPS
-4.05
Earnings Announcement
26-Feb-2025
Previous Close
40.26
Open
40.76
Day's Range
39.79 - 41.145
Year Range
37.77 - 61.61
Trading Volume
35,435
1 Day Change
-0.42%
5 Day Change
-5.91%
1 Month Change
-0.89%
3 Month Change
-21.28%
6 Month Change
-21.55%
Ytd Change
-5.22%
1 Year Change
-4.59%
3 Year Change
56.48%
5 Year Change
115.42%
10 Year Change
299.30%
Max Change
299.30%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.